BioCardia (NASDAQ:BCDA) Receives Buy Rating from HC Wainwright

BioCardia (NASDAQ:BCDA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 35.59% from the company’s current price.

BioCardia Price Performance

BioCardia stock opened at $2.95 on Friday. BioCardia has a 1-year low of $2.62 and a 1-year high of $23.25. The firm has a market capitalization of $5.37 million, a P/E ratio of -0.42 and a beta of 1.37. The company’s 50-day moving average is $3.72 and its 200 day moving average is $5.56.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.35) earnings per share for the quarter. BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 2,208.76%. The firm had revenue of $0.06 million during the quarter. During the same quarter in the prior year, the business earned ($2.55) earnings per share. Research analysts anticipate that BioCardia will post -6.3 earnings per share for the current fiscal year.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.